US20030153528A1 - Hemostatic bone wax composition - Google Patents

Hemostatic bone wax composition Download PDF

Info

Publication number
US20030153528A1
US20030153528A1 US10/267,940 US26794002A US2003153528A1 US 20030153528 A1 US20030153528 A1 US 20030153528A1 US 26794002 A US26794002 A US 26794002A US 2003153528 A1 US2003153528 A1 US 2003153528A1
Authority
US
United States
Prior art keywords
glucosamine
poly
biopolymer
composition
hemostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/267,940
Inventor
Melvin Levinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/267,940 priority Critical patent/US20030153528A1/en
Publication of US20030153528A1 publication Critical patent/US20030153528A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/00412Plasters use for use with needles, tubes or catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/00463Plasters use haemostatic
    • A61F2013/00472Plasters use haemostatic with chemical means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding

Definitions

  • the invention relates to hemostatic compositions useful for surgical applications. More particularly, the invention relates to a hemostatic composition for application to bleeding bone surfaces.
  • Puncture of blood vessels is a necessary stage in many of the minimally invasive approaches to diagnosis and treatment, including interventional radiology and cardiology. Therefore, a need to create hemostasis as rapidly as possible following the procedure becomes an important priority.
  • the cationic substance may be a high molecular weight cationic polyelectrolyte.
  • the cationic polymer is derived from animals (sea life) or plants (fungi, polysaccharides), or synthesized by various processes.
  • Suitable cationic substances are generally available in two forms, i.e., dry powder or an aqueous solution.
  • a dry powder form the cationic substance is used by tapping the cationic particles out from a container onto the hemorrhaging site.
  • the dry powder cationic substance is not easily handled and applied during surgery because it is difficult to quickly measure out the desired amount when a hemorrhaging site is discovered.
  • Cationic substance used in aqueous solution has the disadvantage of diminishing the potency of the cationic substance by dilution.
  • aqueous cationic substance solutions are not stable due to the denaturation and autolysis of the cationic substance in solution. It is therefore an object of the present invention to provide a hemstatically effective, convenient, and storage stable form of cationic substance ideally suited for surgical use.
  • the present invention provides a hemostatic composition, which comprises a hemostatically effective cationic substance and a wax base, wherein the cationic substance is substantially uniformly dispersed in the wax base.
  • the cationic substance can be incorporated into many forms, such as woven and non-woven pads, fibers, gels , pastes, waxes, foams, sprays, liquids of varying viscosities, packings, membranes, sheets, and the like. Additionally, these forms can be incorporated and utilized with iontophoretic types of equipment that create a positive charge at the bleeding site to effect coagulation.
  • colloidal chemistry for effecting coagulation ionically in suspensions or colloidal substance by providing cationic charges, has enormous value in the diagnosis and treatment of conditions such as cardiovascular disease, interventional radiological procedures, and the like.
  • the cationic charge can be provided by a substance with a positively charged surface, or electronically by utilizing electrophoretic type equipment and electrode pads specifically designed to be disposable, conductive and sterile, designed to fit the required anatomical site.
  • Many cationic substances are available, such as polymers, polysaccharides and starches, aluminum salts, magnesium salts, natural polymers such as chitosan, and the like.
  • the invention comprises a hemostatic composition
  • a hemostatic composition comprising a hemostatically effective amount of cationic substance in a wax base.
  • the cationic substance may be folded in as a powder or may be dissolved in biocompatible solutes and added mechanically as a solution.
  • a cationic substance powder is dissolved in a mixture of water and mechanically mixed with a wax base in appropriate ratios and the mixture is dried, preferably freeze-dried to remove the water leaving the particles of cationic substance substantially uniformly dispersed in the wax base.
  • the invention also comprises a process for preparing a hemostatic composition comprising the steps of: admixing an aqueous solution of cationic substance and a wax base, and freeze-drying the mixture to remove substantially all of the water to yield a viscous water soluble wax of cationic substance.
  • the invention further comprises a method for reducing bleeding at a hemorrhaging site by applying a cationic substance wax composition which comprises a hemostatically effective amount of cationic substance in a wax base to the hemorrhaging site of a mammal.
  • the cationic substance may be applied in combination with a fibrous gauze material or by itself in wax form to the hemorrhaging site.
  • the hemostatic cationic wax composition of the present invention provides convenient ready to use hemostatically effective amounts of cationic substance for application to a hemorrhaging surface of a bone.
  • a cationic substance composition is homogeneously dispersed throughout a wax base and remains storage stable until it is ready for use.
  • the cationic substance is a high molecular weight cationic polymer.
  • the cationic polymer may be derived and purified by various processes.
  • the hemostatic properties of related cationic substances have been known for years and prior arts exist for the use of these substances in bleeding situations.
  • the nature of their use in the majority of prior art and expired patents was as a powder, a liquid or as a coated paper or saturated gauze pad.
  • a ready-to-use wax form of the present invention is advantageous over solution forms of cationic substances which must be reconstituted from dry cationic substance powder prior to use. Additionally, cationic substance solutions generally have a low viscosity and a low potency due to their dilute nature. Aqueous solutions of cationic substance are frequently applied in conjunction with, and absorbed on, a coated paper, or saturated gauze dressing because of its low viscosity and potency.
  • the hemostatic cationic substance wax composition of the present invention has a viscosity and potency which is high enough to permit its hemostatically effective use by a surgeon by dipping of a gloved finger into the hemostatic cationic substance wax composition to draw a portion of that composition and placing the drawn portion over the bleeding site.
  • the cationic substance wax composition requires no pre-preparation; it is non-toxic and absorbable by a mammalian body. It can be supplied in a sterile convenient to use delivery system such as a wax tube, jar or containers.
  • the cationic substance wax composition is anti-microbial as well due to the nature of these cationic substances.
  • one embodiment of the invention comprises a mixture of a base of bone wax and a hemostatically effective amount of a cationic substance.
  • Bone wax is a sterile beeswax preparation. It is sometimes formulated as a semi-synthetic mixture of beeswax and softening agents (such as isopropyl palmitate) to make a more pliable product. The product is used to control local bleeding. In neurosurgical and orthopedic procedures, it is used to control bleeding from raw edges of bone.
  • bone wax has some drawbacks in that it must be used sparingly as it may inhibit osteogenesis and limit the healing process by mechanical means. Also studies have shown that there is occasionally mild reaction as well as infection as result of too profuse an application of the wax. Mixing the hemostatic cationic substance into the bone wax can enhance the hemostatic effect of bone wax while retaining its mechanical tamponading ability and allows the good features of the bone wax to be retained while minimizing the amount of the material required to stop the bleeding. By creating the hemostatic composition of the present invention that retains the mechanical tamponade qualities and adherence characteristics of bone wax, while adding a powerful natural hemostatic polymer, the amount of the composition needed is minimized, thereby limiting complications and the known drawbacks of bone wax.
  • a hemostatic cationic substance is formulated together with a bone wax and is packaged sterile in collapsible tubes or containers.
  • the hemostatic cationic substance is in the range 30-60% of the weight of the final wax mixture, but other ranges can be used.
  • the agent may be dissolved in the wax or mechanically mixed.
  • the hemostatic composition in the form of wax to a dressing or directly to the bleeding wound or structure (e.g. bone), presents the substance to the bleeding surface or blood column more easily. Furthermore, the composition in form of wax adapts itself to the surface shape so that greater approximation is accomplished. It may be most efficiently utilized with constant pressure for several minutes after application.
  • the coagulum that forms as a result of the cationic clumping of platelets and blood cells is in addition to the natural clotting cascade and enhances hemstasis to controllable levels. It is also known that may of these cationic polylectrolytes are anti-microbial as well, enhancing the clinical applications.
  • the hemostatic agent is preferably a cationic biopolymer of glucosamine.
  • the cationic biopolymer of glucosamine maybe is in one or more of the following forms: poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine; an acetate salt of poly-D-glucosamine; poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine; and poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
  • the application surface is water soluble. Acidic environments other than an acetate salt, such as lactic acid, can also be incorporated as part
  • the cationic biopolymer of glucosamine is derived from chitosan, which is a collective term applied to deacetylated chitins in various stages of deacetylation and depolymerization.
  • Chitin is the structural polymer of the exo-skeleton of arthropods and cell walls of fungi, and is composed of poly-N-Acetyl glucosamine units. These are linked by Beta 1-4 glycosidic bonds into a linear polymer containing 2,000 to 3,000 units.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A hemostatic composition for effecting hemostasis at a hemorrhaging site comprises a hemostatically effective amount of cationic substance and a wax base, wherein the cationic substance is substantially uniformly dispersed in the bone wax base. The method of preparing the hemostatic composition includes admixing an aqueous solution of a cationic substance and a bone wax, and freeze-drying the mixture to remove substantially all of the water to yield a viscous water soluble composition of fine particles of cationic which is substantially uniformly dispersed throughout the bone wax base. The method for effecting hemostasis comprises making the hemostatic composition and applying a hemostatically effective amount of the hemostatic composition to the hemorrhaging site.

Description

    REFERENCE TO RELATED APPLICATION
  • This application is a continuation in part of U.S. patent application Ser. No. 10/008,052, filed Nov. 13, 2001, the disclosure of which is incorporated herein by reference.[0001]
  • FIELD OF THE INVENTION
  • The invention relates to hemostatic compositions useful for surgical applications. More particularly, the invention relates to a hemostatic composition for application to bleeding bone surfaces. [0002]
  • BACKGROUND OF THE INVENTION
  • Puncture of blood vessels is a necessary stage in many of the minimally invasive approaches to diagnosis and treatment, including interventional radiology and cardiology. Therefore, a need to create hemostasis as rapidly as possible following the procedure becomes an important priority. [0003]
  • The cationic substance may be a high molecular weight cationic polyelectrolyte. Generally, the cationic polymer is derived from animals (sea life) or plants (fungi, polysaccharides), or synthesized by various processes. [0004]
  • Suitable cationic substances are generally available in two forms, i.e., dry powder or an aqueous solution. In a dry powder form, the cationic substance is used by tapping the cationic particles out from a container onto the hemorrhaging site. The dry powder cationic substance is not easily handled and applied during surgery because it is difficult to quickly measure out the desired amount when a hemorrhaging site is discovered. Cationic substance used in aqueous solution has the disadvantage of diminishing the potency of the cationic substance by dilution. Further, aqueous cationic substance solutions are not stable due to the denaturation and autolysis of the cationic substance in solution. It is therefore an object of the present invention to provide a hemstatically effective, convenient, and storage stable form of cationic substance ideally suited for surgical use. [0005]
  • SUMMARY OF THE INVENTION
  • The present invention provides a hemostatic composition, which comprises a hemostatically effective cationic substance and a wax base, wherein the cationic substance is substantially uniformly dispersed in the wax base. [0006]
  • Many hemostasis methods have been utilized or attempted, including suture-based devices, collagen plugs, pressure applying devices, and the like. The situation is complicated further by the use of anticoagulants in these procedures, which prolongs clotting times. Substances such as heparin, aspirin, coumadin, and other anticoagulants are used with regularity and affect the normal blood coagulation cascade. The use of cationic substances in flocculation and coagulation in non-medical situations such as water treatment, paper production, industrial sludge treatment, and the like has been effectively used in the past and is well documented. The method of action is by precipitating, coagulating or flocculating suspended particles which are negatively charged by virtue of using positively charged materials, which attract the oppositely charged ions. [0007]
  • It has been clearly demonstrated that the charge on blood cells and components (platelets, etc.) is negative. By using a positively charged biocompatible substance, it is possible to agglomerate these cells creating coagulation through a system other than by virtue of the normal clotting cascade. Innocuous polymers are positively charged (cationic substances) as the initiator of coagulation in clinical situations. Additionally, positive charges can be applied via iontophoretic methods using electrode pads and positively charged treatment sites to accomplish the same thing. [0008]
  • The use of a positive charge administered by either cationic substances or by iontophoretic means to quickly create a coagulation process and hemostasis until the normal clotting cascade can take over. This can occur even in the face of significant anticoagulation since the process is ionic and not effected by the anticoagulants, which operate on the normal blood cascade. This approach can be revolutionary in the after treatment of patients with minimally invasive or invasive procedures since rapid hemostasis and mobilization of the patient are desirable endpoints. [0009]
  • The cationic substance can be incorporated into many forms, such as woven and non-woven pads, fibers, gels , pastes, waxes, foams, sprays, liquids of varying viscosities, packings, membranes, sheets, and the like. Additionally, these forms can be incorporated and utilized with iontophoretic types of equipment that create a positive charge at the bleeding site to effect coagulation. [0010]
  • Utilizing colloidal chemistry for effecting coagulation ionically in suspensions or colloidal substance by providing cationic charges, has enormous value in the diagnosis and treatment of conditions such as cardiovascular disease, interventional radiological procedures, and the like. The cationic charge can be provided by a substance with a positively charged surface, or electronically by utilizing electrophoretic type equipment and electrode pads specifically designed to be disposable, conductive and sterile, designed to fit the required anatomical site. Many cationic substances are available, such as polymers, polysaccharides and starches, aluminum salts, magnesium salts, natural polymers such as chitosan, and the like. [0011]
  • The use of ionic charges to create hemostasis is a new and important process in the treatment of disease processes. This novel approach can be administered by applying sterile, biocompatible, positively charged materials directly in contact with the blood column, accompanied by pressure, or provided electronically by utilizing controlled direct current on the positive side with iontophoretic type approaches and specially constructed, disposable, sterile electrodes to the bleeding site [0012]
  • In accordance with purposes of the invention, as embodied and fully described herein, the invention comprises a hemostatic composition comprising a hemostatically effective amount of cationic substance in a wax base. The cationic substance may be folded in as a powder or may be dissolved in biocompatible solutes and added mechanically as a solution. Preferably, a cationic substance powder is dissolved in a mixture of water and mechanically mixed with a wax base in appropriate ratios and the mixture is dried, preferably freeze-dried to remove the water leaving the particles of cationic substance substantially uniformly dispersed in the wax base. [0013]
  • The invention also comprises a process for preparing a hemostatic composition comprising the steps of: admixing an aqueous solution of cationic substance and a wax base, and freeze-drying the mixture to remove substantially all of the water to yield a viscous water soluble wax of cationic substance. [0014]
  • The invention further comprises a method for reducing bleeding at a hemorrhaging site by applying a cationic substance wax composition which comprises a hemostatically effective amount of cationic substance in a wax base to the hemorrhaging site of a mammal. The cationic substance may be applied in combination with a fibrous gauze material or by itself in wax form to the hemorrhaging site.[0015]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Reference will now be made in detail to preferred embodiments of the invention. [0016]
  • The hemostatic cationic wax composition of the present invention provides convenient ready to use hemostatically effective amounts of cationic substance for application to a hemorrhaging surface of a bone. A cationic substance composition is homogeneously dispersed throughout a wax base and remains storage stable until it is ready for use. [0017]
  • The cationic substance is a high molecular weight cationic polymer. The cationic polymer may be derived and purified by various processes. The hemostatic properties of related cationic substances have been known for years and prior arts exist for the use of these substances in bleeding situations. The nature of their use in the majority of prior art and expired patents was as a powder, a liquid or as a coated paper or saturated gauze pad. [0018]
  • A ready-to-use wax form of the present invention is advantageous over solution forms of cationic substances which must be reconstituted from dry cationic substance powder prior to use. Additionally, cationic substance solutions generally have a low viscosity and a low potency due to their dilute nature. Aqueous solutions of cationic substance are frequently applied in conjunction with, and absorbed on, a coated paper, or saturated gauze dressing because of its low viscosity and potency. The hemostatic cationic substance wax composition of the present invention has a viscosity and potency which is high enough to permit its hemostatically effective use by a surgeon by dipping of a gloved finger into the hemostatic cationic substance wax composition to draw a portion of that composition and placing the drawn portion over the bleeding site. [0019]
  • The cationic substance wax composition requires no pre-preparation; it is non-toxic and absorbable by a mammalian body. It can be supplied in a sterile convenient to use delivery system such as a wax tube, jar or containers. The cationic substance wax composition is anti-microbial as well due to the nature of these cationic substances. [0020]
  • In accordance with the purposes of the invention, as embodied and fully described herein, one embodiment of the invention comprises a mixture of a base of bone wax and a hemostatically effective amount of a cationic substance. [0021]
  • Bone wax is a sterile beeswax preparation. It is sometimes formulated as a semi-synthetic mixture of beeswax and softening agents (such as isopropyl palmitate) to make a more pliable product. The product is used to control local bleeding. In neurosurgical and orthopedic procedures, it is used to control bleeding from raw edges of bone. [0022]
  • The use of bone wax has some drawbacks in that it must be used sparingly as it may inhibit osteogenesis and limit the healing process by mechanical means. Also studies have shown that there is occasionally mild reaction as well as infection as result of too profuse an application of the wax. Mixing the hemostatic cationic substance into the bone wax can enhance the hemostatic effect of bone wax while retaining its mechanical tamponading ability and allows the good features of the bone wax to be retained while minimizing the amount of the material required to stop the bleeding. By creating the hemostatic composition of the present invention that retains the mechanical tamponade qualities and adherence characteristics of bone wax, while adding a powerful natural hemostatic polymer, the amount of the composition needed is minimized, thereby limiting complications and the known drawbacks of bone wax. [0023]
  • In this invention, a hemostatic cationic substance is formulated together with a bone wax and is packaged sterile in collapsible tubes or containers. Preferably, the hemostatic cationic substance is in the range 30-60% of the weight of the final wax mixture, but other ranges can be used. The agent may be dissolved in the wax or mechanically mixed. [0024]
  • Applying the hemostatic composition in the form of wax to a dressing or directly to the bleeding wound or structure (e.g. bone), presents the substance to the bleeding surface or blood column more easily. Furthermore, the composition in form of wax adapts itself to the surface shape so that greater approximation is accomplished. It may be most efficiently utilized with constant pressure for several minutes after application. The coagulum that forms as a result of the cationic clumping of platelets and blood cells is in addition to the natural clotting cascade and enhances hemstasis to controllable levels. It is also known that may of these cationic polylectrolytes are anti-microbial as well, enhancing the clinical applications. [0025]
  • In the above embodiments, the hemostatic agent is preferably a cationic biopolymer of glucosamine. The cationic biopolymer of glucosamine maybe is in one or more of the following forms: poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine; an acetate salt of poly-D-glucosamine; poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine; and poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine. In forms including an acetate salt, the application surface is water soluble. Acidic environments other than an acetate salt, such as lactic acid, can also be incorporated as part of the biopolymer of glucosamine. [0026]
  • In a preferred form, the cationic biopolymer of glucosamine is derived from chitosan, which is a collective term applied to deacetylated chitins in various stages of deacetylation and depolymerization. Chitin is the structural polymer of the exo-skeleton of arthropods and cell walls of fungi, and is composed of poly-N-Acetyl glucosamine units. These are linked by Beta 1-4 glycosidic bonds into a linear polymer containing 2,000 to 3,000 units. [0027]
  • The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. [0028]

Claims (38)

What is claimed is:
1. A hemostatic composition comprising:
a hemostatically effective amount of hemostatic cationic substance; and
a base in a form of wax, and wherein said hemostatic cationic substance is substantially uniformly dispersed in said base.
2. The composition of claim 1, wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,
3. The composition of claim 2, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
4. The composition of claim 2, wherein the biopolymer of glucosamine is poly-D-glucosamine.
5. The composition of claim 2, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
6. The composition of claim 2, wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
7. The composition of claim 2, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
8. The composition of claim 2, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
9. The composition of claim 2, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
10. The composition of claim 2, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
11. The composition of claim 1, wherein said base is bone wax.
12. The composition of claim 1, wherein said base is water-soluble.
13. The composition of claim 1 further includes an anti-microbial material.
14. A method for making a hemostatic composition comprising:
mixing a hemostatically effective amount of hemostatic cationic substance and a base, wherein said base is in a form of wax.
15. The method of claim 14, wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,
16. The method of claim 15, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
17. The method of claim 15, wherein the biopolymer of glucosamine is poly-D-glucosamine.
18. The method of claim 15, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
19. The method of claim 15, wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
20. The method of claim 15, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
21. The method of claim 15, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
22. The method of claim 15, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
23. The method of claim 15, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
24. The method of claim 14, wherein said base is bone wax.
25. The method of claim 14, wherein said base is water-soluble.
26. The method of claim 14 further includes a step of mixing an anti-microbial material in said composition.
27. A method for effecting hemostatic composition at a hemorrhaging site in a mammal comprising:
A). forming a hemostatic composition by mixing a hemostatically effective amount of hemostatic cationic substance and a base, wherein said base is in form of wax; and
B). applying a hemostatic effective amount of said hemostatic composition to the hemorrhaging site of the mammal.
28. The method of claim 27, wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,
29. The method of claim 28, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
30. The method of claim 28, wherein the biopolymer of glucosamine is poly-D-glucosamine.
31. The method of claim 28, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
32. The method of claim 28, wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
33. The method of claim 28, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
34. The method of claim 28, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
35. The method of claim 28, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
36. The method of claim 28, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
37. The method of claim 27, wherein said base is bone wax.
38. The method of claim 27 further includes maintaining pressure for a predetermined time on the hemorrhaging site after applying said hemostatic composition to the hemorrhaging site of the mammal.
US10/267,940 2001-11-13 2002-10-09 Hemostatic bone wax composition Abandoned US20030153528A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/267,940 US20030153528A1 (en) 2001-11-13 2002-10-09 Hemostatic bone wax composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/008,052 US20030093114A1 (en) 2001-11-13 2001-11-13 Method for effecting hemostasis
US10/267,940 US20030153528A1 (en) 2001-11-13 2002-10-09 Hemostatic bone wax composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/008,052 Continuation-In-Part US20030093114A1 (en) 2001-11-13 2001-11-13 Method for effecting hemostasis

Publications (1)

Publication Number Publication Date
US20030153528A1 true US20030153528A1 (en) 2003-08-14

Family

ID=21729584

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/008,052 Pending US20030093114A1 (en) 2001-11-13 2001-11-13 Method for effecting hemostasis
US10/267,940 Abandoned US20030153528A1 (en) 2001-11-13 2002-10-09 Hemostatic bone wax composition
US10/267,902 Abandoned US20030148994A1 (en) 2001-11-13 2002-10-09 Hemostatic composition
US10/286,566 Expired - Lifetime US6890344B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US10/286,614 Expired - Lifetime US6638296B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US11/125,765 Abandoned US20050222615A1 (en) 2001-11-13 2005-05-10 Hemostasis pad and method

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/008,052 Pending US20030093114A1 (en) 2001-11-13 2001-11-13 Method for effecting hemostasis

Family Applications After (4)

Application Number Title Priority Date Filing Date
US10/267,902 Abandoned US20030148994A1 (en) 2001-11-13 2002-10-09 Hemostatic composition
US10/286,566 Expired - Lifetime US6890344B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US10/286,614 Expired - Lifetime US6638296B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US11/125,765 Abandoned US20050222615A1 (en) 2001-11-13 2005-05-10 Hemostasis pad and method

Country Status (3)

Country Link
US (6) US20030093114A1 (en)
AU (1) AU2002363798A1 (en)
WO (1) WO2003041564A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122361A1 (en) * 2005-11-29 2007-05-31 Weitao Jia Tooth colorant and whitener, method of manufacture, and method of use thereof
CN101862469A (en) * 2010-05-28 2010-10-20 武汉锐尔生物科技有限公司 Chitosan derivative quick hemostasis granules and preparation method thereof
US20110189304A1 (en) * 2003-09-23 2011-08-04 Kronenthal Richard L Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US20120027817A1 (en) * 2003-09-23 2012-02-02 Orthocon, Inc. Absorbable Implants and Methods for Their Use in Hemostasis
US20130330416A1 (en) * 2012-06-08 2013-12-12 Robert J. Greenwald Styptic Storage and Delivery

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998510B2 (en) * 2002-02-04 2006-02-14 Damage Control Surgical Technologies, Inc. Method and apparatus for improved hemostasis and damage control operations
AU2003294238A1 (en) * 2002-10-30 2004-06-07 Joel S. Rossen Simplified one-handed preemptive medical procedure site dressing to prevent sharps injuries and exposure to bloodborne pathogens
US7943810B2 (en) 2003-02-04 2011-05-17 Buckman Robert F Method and apparatus for hemostasis
US20050267520A1 (en) 2004-05-12 2005-12-01 Modesitt D B Access and closure device and method
US7678133B2 (en) 2004-07-10 2010-03-16 Arstasis, Inc. Biological tissue closure device and method
US20060276836A1 (en) * 2005-06-07 2006-12-07 Bergin Patrick J Hemostatic wire guided bandage and method of use
US20060276838A1 (en) * 2005-06-07 2006-12-07 Wensel Jeffrey P Vascular puncture sealing method, apparatus, and system
US20080015481A1 (en) * 2005-05-04 2008-01-17 Bergin Patrick J Hemostatic bandage and method of use
US7622628B2 (en) * 2005-05-04 2009-11-24 Innovasa Corporation Hemostatic wire guided bandage and method of use
EP1885260A4 (en) 2005-05-12 2015-01-21 Arstasis Inc Access and closure device and method
US20080269659A1 (en) * 2005-06-07 2008-10-30 Bergin Patrick J Hemostatic Bandage
US20070154510A1 (en) * 2005-12-30 2007-07-05 Wilcher Steve A Adsorbent-Containing Hemostatic Devices
US20070154509A1 (en) * 2005-12-30 2007-07-05 Wilcher Steve A Adsorbent-Containing Hemostatic Devices
US8277837B2 (en) 2006-01-11 2012-10-02 Entegrion, Inc. Hemostatic textile
US7905852B2 (en) 2006-05-16 2011-03-15 Barbara Jennings-Spring Skin-contacting-adhesive free dressing
US7645252B2 (en) 2006-05-16 2010-01-12 Barbara Brooke Jennings-Spring Body or plant part dressing
US20090287133A1 (en) * 2006-06-06 2009-11-19 Lagreca Sr Alfred J Disposable or Reclosable Wound or Skin Condition Dressing and Treatment System
US20080097270A1 (en) * 2006-08-25 2008-04-24 Utterberg David S Resilient hemostasis devices
US20080063697A1 (en) * 2006-09-08 2008-03-13 Bedard Robert L Use of Unactivated Calcium Exchanged Zeolites in Hemostatic Devices and Products
US8623842B2 (en) 2006-09-27 2014-01-07 Hemostasis, Llc Hemostatic agent and method
US8100937B2 (en) 2006-10-10 2012-01-24 Smalling Medical Ventures, Llc Pressure assist system for facilitating vascular hemostasis, and associated method
US7931651B2 (en) 2006-11-17 2011-04-26 Wake Lake University Health Sciences External fixation assembly and method of use
US20080145455A1 (en) * 2006-12-13 2008-06-19 Bedard Robert L Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents
US8932560B2 (en) * 2007-09-04 2015-01-13 University of Maryland, College Parke Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells
US9066885B2 (en) * 2007-03-16 2015-06-30 University Of Maryland, College Park Advanced functional biocompatible polymeric matrix containing nano-compartments
US8597253B2 (en) 2007-04-20 2013-12-03 Bard Access Systems Huber needle with safety sheath
US20090047366A1 (en) * 2007-08-15 2009-02-19 Bedard Robert L Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants
US8883194B2 (en) * 2007-11-09 2014-11-11 Honeywell International, Inc. Adsorbent-containing hemostatic devices
US8795718B2 (en) * 2008-05-22 2014-08-05 Honeywell International, Inc. Functional nano-layered hemostatic material/device
EP2313008B1 (en) 2008-07-18 2017-04-12 Wake Forest University Health Sciences Apparatus for cardiac tissue modulation by topical application of vacuum to minimize cell death and damage
US8979882B2 (en) 2008-07-21 2015-03-17 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
US20110112572A1 (en) * 2009-11-10 2011-05-12 Tyco Healthcare Group Lp Hemostatic Tapes and Dispensers Therefor
US20110108199A1 (en) * 2009-11-10 2011-05-12 Tyco Healthcare Group Lp Hemostatic Tapes and Dispensers Therefor
US8668899B2 (en) 2009-11-13 2014-03-11 University Of Maryland, College Park Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
US8302323B2 (en) 2010-06-21 2012-11-06 Confluent Surgical, Inc. Hemostatic patch
CN103260654B (en) * 2010-07-14 2015-07-22 Cr巴德公司 A dressing device for use with a cannula or a catheter
WO2012021877A2 (en) 2010-08-13 2012-02-16 University Of Maryland, College Park Method and system for reversal of interactions between hydrophobically modified biopolymers and vesicles or cell membranes
US9248234B2 (en) 2010-09-10 2016-02-02 C. R. Bard, Inc. Systems for isolation of a needle-based infusion set
US10525234B2 (en) 2010-09-10 2020-01-07 C. R. Bard, Inc. Antimicrobial/haemostatic interface pad for placement between percutaneously placed medical device and patient skin
US20140066894A1 (en) 2010-09-10 2014-03-06 C. R. Bard, Inc. Self-Sealing Pad for a Needle-Based Infusion Set
US9427360B2 (en) 2010-11-04 2016-08-30 W. Jerry Mezger Hemostatic fabric
WO2012075457A2 (en) 2010-12-02 2012-06-07 University Of Maryland, College Park Method and system for capture and use of intact vesicles on electrodeposited hydrophobically modified biopolymer films
US9561300B2 (en) 2011-09-26 2017-02-07 Yes, Inc. Hemostatic compositions and dressings for bleeding
US20130317438A1 (en) 2012-05-25 2013-11-28 Arstasis, Inc. Vascular access configuration
US20130317481A1 (en) 2012-05-25 2013-11-28 Arstasis, Inc. Vascular access configuration
WO2014015347A1 (en) 2012-07-20 2014-01-23 Aegis Women's Health Technologies Compositions and methods for preventing infectious diseases in females
US8969649B2 (en) * 2012-08-10 2015-03-03 Ethicon, Inc. Integrated dressing device
US10085892B2 (en) 2013-03-07 2018-10-02 Life Sciences Llc Apparatus and method for wound infection prevention
WO2014160136A1 (en) 2013-03-13 2014-10-02 University Of Maryland, Office Of Technology Commercialization Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
US8961479B2 (en) 2013-03-19 2015-02-24 Biolife, L.L.C. Hemostatic device and method
US20150057640A1 (en) * 2013-08-22 2015-02-26 Evelyn M. Tarkington Circular bandage for drain tube
US10195399B2 (en) 2013-10-29 2019-02-05 Avent, Inc. Catheter securement device
US9764116B2 (en) 2013-12-30 2017-09-19 Avent, Inc. Catheter insertion site plug
US10556093B2 (en) 2013-12-31 2020-02-11 Confluence, LLC Medical devices, dressings, and methods for closing openings in tissue
US10406255B2 (en) 2014-05-28 2019-09-10 Highland Industries, Inc. Hemostatic textile
US11627795B2 (en) 2017-02-14 2023-04-18 G-Tech Llc Shoulder transfer weight support system and face shield
WO2019221201A1 (en) * 2018-05-16 2019-11-21 テルモ株式会社 Compression device and compression method
CN110538024B (en) * 2019-09-03 2022-06-14 重庆市渝北区人民医院 Portable medical pressurizing application device, use method and application
WO2021134005A1 (en) * 2019-12-27 2021-07-01 Hg Medical Technologies Llc Iontophoretic wound treatment device
US11272941B1 (en) 2020-08-07 2022-03-15 William P Buchanan Secondary device holder and compression system, method of making and using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635818A (en) * 1968-12-06 1972-01-18 Maria Gertrude Muzzarelli Chitin and chitosan as chromatographic supports and adsorbents for collection of metal ions from organic and aqueous solutions and sea water
US3969189A (en) * 1971-12-14 1976-07-13 Kumiai Chemical Industry Co., Ltd. Cell wall-lysing complex enzymes and a process for the production thereof
US5166187A (en) * 1987-06-15 1992-11-24 Centre National De La Recherche Biomaterials with a base of mixtures of collagen, chitosan and glycosaminoglycans, process for preparing them and their application in human medicine
US20020160098A1 (en) * 1998-09-22 2002-10-31 Zamora Paul O. Nucleic acid coating compositions and methods
US20030050589A1 (en) * 2000-04-06 2003-03-13 Mcdevitt Jason P. Disposable finger sleeve for appendages

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632754A (en) * 1968-02-12 1972-01-04 Lescarden Ltd Use of chitin for promoting wound healing
US3811438A (en) 1972-03-30 1974-05-21 G Economou Adhesive tapes and bandages
US4059097A (en) * 1976-11-03 1977-11-22 American Cyanamid Company Method of minimizing tissue reaction during surgery with chitin
US4394373A (en) * 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US4532134A (en) * 1981-04-06 1985-07-30 Malette William Graham Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound
US5203764A (en) * 1985-10-04 1993-04-20 Minnesota Mining And Manufacturing Company Foam pads useful in wound management
US4833238A (en) * 1986-12-16 1989-05-23 E. I. Du Pont De Nemours And Company High strength fibers from chitin derivatives
US4784653A (en) * 1987-06-22 1988-11-15 Johnson & Johnson Patient Care, Inc. Absorbent adhesive dressing
US5086764A (en) * 1989-04-13 1992-02-11 Thomas Gilman Absorbent dressing
US4981133A (en) * 1989-10-10 1991-01-01 Rollband Ernest J Pressure bandage for puncture wounds with a target marketing
US5310402A (en) * 1990-12-03 1994-05-10 Rollband Ernest J Temporary bandage tape
US5324252A (en) * 1991-03-25 1994-06-28 Minnesota Mining And Manufacturing Company Foam pads useful in wound management
US5429591A (en) * 1991-07-22 1995-07-04 Nitto Denko Corporation Absorbent dressing having backing and continuous adhesive layer
US5269803A (en) * 1992-04-10 1993-12-14 Gtr Patent, Inc. Hemostasis pressure pad band
US5375588A (en) * 1992-08-17 1994-12-27 Yoon; Inbae Method and apparatus for use in endoscopic procedures
US5336219A (en) * 1993-03-23 1994-08-09 Medi-Flex Hospital Products, Inc. Skin closure system
US5683354A (en) * 1993-07-06 1997-11-04 Levy; Raymond H. Adhesive bandage for a digit of a human hand or foot
US5486195A (en) * 1993-07-26 1996-01-23 Myers; Gene Method and apparatus for arteriotomy closure
US5653730A (en) * 1993-09-28 1997-08-05 Hemodynamics, Inc. Surface opening adhesive sealer
US5714543A (en) * 1994-01-13 1998-02-03 Bristol-Myers Squibb Company Water soluble polymer additives for polyurethane-based pressure sensitive adhesives
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5533962A (en) * 1995-05-12 1996-07-09 Peterman; Shadi Ringless adhesive bandage
US5795317A (en) * 1995-06-07 1998-08-18 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
US5836970A (en) 1996-08-02 1998-11-17 The Kendall Company Hemostatic wound dressing
US5807341A (en) * 1996-12-11 1998-09-15 Team Medical Llc Medical catheter dressing device
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
US6478808B2 (en) * 1997-12-17 2002-11-12 Closys Corporation Clotting cascade initiating apparatus and methods of use and methods of closing wounds
US20020015724A1 (en) * 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
US6060461A (en) * 1999-02-08 2000-05-09 Drake; James Franklin Topically applied clotting material
ES2269069T3 (en) 1999-06-08 2007-04-01 Ethicon, Inc. WOVEN SURGICAL MESH.
US6984219B2 (en) * 1999-09-23 2006-01-10 Mark Ashby Depth and puncture control for blood vessel hemostasis system
US6586651B2 (en) * 1999-11-01 2003-07-01 John Patrick Sullivan Adhensive bandage with soft, three-dimensional toy
US6316686B1 (en) * 2000-06-20 2001-11-13 Timothy N. Byrd Medical pressure dressing and process

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635818A (en) * 1968-12-06 1972-01-18 Maria Gertrude Muzzarelli Chitin and chitosan as chromatographic supports and adsorbents for collection of metal ions from organic and aqueous solutions and sea water
US3969189A (en) * 1971-12-14 1976-07-13 Kumiai Chemical Industry Co., Ltd. Cell wall-lysing complex enzymes and a process for the production thereof
US5166187A (en) * 1987-06-15 1992-11-24 Centre National De La Recherche Biomaterials with a base of mixtures of collagen, chitosan and glycosaminoglycans, process for preparing them and their application in human medicine
US20020160098A1 (en) * 1998-09-22 2002-10-31 Zamora Paul O. Nucleic acid coating compositions and methods
US20030050589A1 (en) * 2000-04-06 2003-03-13 Mcdevitt Jason P. Disposable finger sleeve for appendages

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189304A1 (en) * 2003-09-23 2011-08-04 Kronenthal Richard L Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US20120027817A1 (en) * 2003-09-23 2012-02-02 Orthocon, Inc. Absorbable Implants and Methods for Their Use in Hemostasis
US8337879B2 (en) 2003-09-23 2012-12-25 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US20070122361A1 (en) * 2005-11-29 2007-05-31 Weitao Jia Tooth colorant and whitener, method of manufacture, and method of use thereof
CN101862469A (en) * 2010-05-28 2010-10-20 武汉锐尔生物科技有限公司 Chitosan derivative quick hemostasis granules and preparation method thereof
US20130330416A1 (en) * 2012-06-08 2013-12-12 Robert J. Greenwald Styptic Storage and Delivery
US8658193B2 (en) * 2012-06-08 2014-02-25 Robert J. Greenwald Styptic storage and delivery

Also Published As

Publication number Publication date
US20030093115A1 (en) 2003-05-15
US20030148994A1 (en) 2003-08-07
WO2003041564A2 (en) 2003-05-22
US20050222615A1 (en) 2005-10-06
US20030093075A1 (en) 2003-05-15
US6638296B2 (en) 2003-10-28
AU2002363798A1 (en) 2003-05-26
WO2003041564A3 (en) 2003-12-04
US20030093114A1 (en) 2003-05-15
US6890344B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
US20030153528A1 (en) Hemostatic bone wax composition
US10195312B2 (en) Modified starch material of biocompatible hemostasis
EP2203053B1 (en) Modified starch material of biocompatible hemostasis
CN106983905B (en) A kind of injectable type self-healing hemostatic material and its preparation method and application
EP2076246B1 (en) Formation of medically useful gels comprising microporous particles and methods of use
US20080145455A1 (en) Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents
EP2233157A1 (en) A biocompatible denatured starch sponge material
US6258995B1 (en) Wound treatment composition
CN114949334A (en) Degradable haemostat composition
JPH04505267A (en) Improvements in or relating to pharmaceutical preparations
CN104208741A (en) Chitosan based adhesive bandage
CN113144280B (en) Intelligent antibacterial hydrogel and application thereof
WO2021128050A1 (en) Hemostatic paste and uses thereof
CN116999607A (en) Self-gelling quick hemostatic powder and preparation method and application thereof
EP0968009B1 (en) Wound dressing gel
EP1109584A1 (en) A composition capable of absorbing fluid
JP2010513291A (en) Inorganic solids that accelerate blood clotting
CN109568635B (en) In-situ expansion high-water-absorption hemostatic material and preparation method thereof
CN115887738A (en) Polyacrylamide-chitosan/kaolin porous material and preparation method thereof
RU2775940C2 (en) Composition for wound bandages
MX2007004802A (en) Molecular sieve materials having increased particle size for the formation of blood clots

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION